Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
暂无分享,去创建一个
S. Fröhling | B. Verdoodt | U. Mansmann | V. Heinemann | H. Glimm | A. Tannapfel | A. Maghnouj | S. Hahn | R. Viebahn | Laura J. Godfrey | M. Marqués | T. Schiergens | N. Casadei | H. Wolters | D. Vangala | J. Siveke | C. Ball | S. Stintzing | D. Edelstein | M. Pohl | S. Liffers | S. Klein-Scory | J. Werner | Wolff Schmiegel | C. Teschendorf | J. Kumbrink | S. Ladigan | A. Jung | Martina K. Zowada | D. Lindoerfer | C. Bernhardt | Jaime Martínez de Villarreal | J. Stern | Mario Huerta | Selami Usta | Soha Noseir | T. Götze | Jacob Admard | Nicolas Casadei | W. Schmiegel | Doris Lindoerfer
[1] S. Fröhling,et al. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models , 2021, Genome Medicine.
[2] Brian T. Lee,et al. The UCSC Genome Browser database: 2021 update , 2020, Nucleic Acids Research.
[3] W. Scheithauer,et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial , 2020, British Journal of Cancer.
[4] S. Dawson,et al. Non-genetic mechanisms of therapeutic resistance in cancer , 2020, Nature Reviews Cancer.
[5] A. Matsuda,et al. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy , 2020, International Journal of Clinical Oncology.
[6] Gerben Menschaert,et al. mQC: A post-mapping data exploration tool for ribosome profiling , 2019, Comput. Methods Programs Biomed..
[7] Joon-Oh Park,et al. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients , 2019, Scientific Reports.
[8] Yixin Zeng,et al. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study , 2019, Asia-Pacific journal of clinical oncology.
[9] Ryan L. Collins,et al. The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.
[10] M. Gerlinger,et al. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer , 2018, bioRxiv.
[11] Margaret P. Chapman,et al. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer , 2018, Nature Communications.
[12] Benjamin Werner,et al. Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. , 2018, Cancer discovery.
[13] P. Gibbs,et al. Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer , 2018, Clinical Cancer Research.
[14] Amos Bairoch,et al. The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.
[15] Jia Gu,et al. fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.
[16] P. Delvenne,et al. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases , 2018, Oncogene.
[17] A. Bardelli,et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] B. Taylor,et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS , 2017, Nature.
[19] Elisa Ficarra,et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.
[20] Michael P. Schroeder,et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.
[21] Sydney M. Shaffer,et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.
[22] M. Ychou,et al. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer , 2017, Clinical Cancer Research.
[23] Shawn M. Gillespie,et al. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.
[24] S. Tomida,et al. Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies , 2017, Molecular carcinogenesis.
[25] A. Bardelli,et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer , 2016, Nature Communications.
[26] F. Diehl,et al. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing , 2016, PloS one.
[27] A. Bardelli,et al. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer , 2016, Clinical Cancer Research.
[28] P. Bauer,et al. SeqPurge: highly-sensitive adapter trimming for paired-end NGS data , 2016, BMC Bioinformatics.
[29] A. Heger,et al. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy , 2016, bioRxiv.
[30] Etienne Becht,et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.
[31] M. Cheang,et al. Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC) , 2016, Oncotarget.
[32] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, bioRxiv.
[33] Bruce A. Posner,et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.
[34] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.
[35] E. Nishida,et al. HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer. , 2015, Cancer cell.
[36] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[37] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[38] R. Scharpf,et al. The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.
[39] M. Nowak,et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.
[40] Rodrigo Dienstmann,et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. , 2015, Cancer discovery.
[41] Beatriz Bellosillo,et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.
[42] N. Normanno,et al. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models , 2015, Clinical Cancer Research.
[43] Marco Beccuti,et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.
[44] Sabine Tejpar,et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies , 2015, Science Translational Medicine.
[45] P. Angenendt,et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] M. Salido,et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.
[47] E. Batlle,et al. Iro/IRX transcription factors negatively regulate Dpp/TGF‐β pathway activity during intestinal tumorigenesis , 2014, EMBO reports.
[48] Ho-June Lee,et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.
[49] F. Ciardiello,et al. Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition , 2014, Clinical Cancer Research.
[50] Christopher J. Ott,et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.
[51] S. Stylli,et al. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity , 2014, Cancer biology & therapy.
[52] A. Bardelli,et al. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.
[53] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[54] Andrew E. Teschendorff,et al. ChAMP: 450k Chip Analysis Methylation Pipeline , 2014, Bioinform..
[55] G. Botti,et al. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies , 2013, Cancer biology & therapy.
[56] Andrea Bertotti,et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.
[57] Marzieh Niknami,et al. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. , 2013, Biochimica et biophysica acta.
[58] Shuxia Zhao,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.
[59] W. Shi,et al. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote , 2013, Nucleic acids research.
[60] X. Pivot,et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. , 2013, Clinical colorectal cancer.
[61] W. Seeger,et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF , 2013, Oncogene.
[62] Wendy Winckler,et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2 , 2012, Proceedings of the National Academy of Sciences.
[63] Gabor T. Marth,et al. Haplotype-based variant detection from short-read sequencing , 2012, 1207.3907.
[64] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[65] M. Gupta,et al. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy , 2012, Leukemia.
[66] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[67] S. Quake,et al. Identification of a cKit(+) colonic crypt base secretory cell that supports Lgr5(+) stem cells in mice. , 2012, Gastroenterology.
[68] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[69] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[70] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[71] P. Jänne,et al. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.
[72] Michael C. Rusch,et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.
[73] S. Cohn,et al. Fibroblast Growth Factor Receptor-3 (FGFR-3) Regulates Expression of Paneth Cell Lineage-specific Genes in Intestinal Epithelial Cells through both TCF4/β-Catenin-dependent and -independent Signaling Pathways* , 2011, The Journal of Biological Chemistry.
[74] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[75] R. Berardi,et al. Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan , 2010, International journal of cancer.
[76] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[77] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[78] J. Vandesompele,et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] J. Budczies,et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. , 2009, Gastroenterology.
[80] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[81] D. Largaespada,et al. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. , 2009, Cancer research.
[82] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] R. Carano,et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models , 2008, Oncogene.
[84] Jianren Gu,et al. Ciliary neurotrophic factor receptor α subunit–modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications , 2007, Hepatology.
[85] K. Kinzler,et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.
[86] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Frank Diehl,et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.
[88] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[89] N. Dumaz,et al. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways , 2005, The FEBS journal.
[90] M. Hofker. Faculty Opinions recommendation of PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. , 2003 .
[91] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[92] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[93] I. Tsigelny,et al. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. , 2018, Cancer discovery.
[94] E. Gál,et al. Iro / Irx transcription factors negatively regulate Dpp / TGF-β pathway activity during intestinal tumorigenesis , 2014 .
[95] Wilhelm G Dirks,et al. STR DNA typing of human cell lines: detection of intra- and interspecies cross-contamination. , 2013, Methods in molecular biology.
[96] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[97] Ira M. Hall,et al. BEDTools: a flexible suite of utilities for comparing genomic features , 2010, Bioinform..
[98] Luigi Naldini,et al. Stable knockdown of microRNA in vivo by lentiviral vectors , 2009, Nature Methods.
[99] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..
[100] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..